Platelet Aggregation Clinical Trials

7 recruitingLast updated: June 20, 2026

There are 7 actively recruiting platelet aggregation clinical trials across 7 countries. Studies span Not Applicable, Phase 1, Phase 4. Top locations include Banja Luka, Bosnia and Herzegovina, Bern, Switzerland, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Platelet Aggregation Trials at a Glance

7 actively recruiting trials for platelet aggregation are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Banja Luka, Bern, and Boston. Lead sponsors running platelet aggregation studies include Insel Gruppe AG, University Hospital Bern, Massachusetts General Hospital, and Fondazione Ricerca e Innovazione Cardiovascolare ETS.

Browse platelet aggregation trials by phase

Treatments under study

About Platelet Aggregation Clinical Trials

Looking for clinical trials for Platelet Aggregation? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Platelet Aggregation trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Platelet Aggregation clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 4

AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE

Atrial FibrillationStrokePlatelet Aggregation Inhibitors+2 more
University Hospital, Bordeaux60 enrolled2 locationsNCT04796714
Recruiting
Not Applicable

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

ThrombosisAmputationPlatelet Aggregation Inhibitors+4 more
Massachusetts General Hospital484 enrolled2 locationsNCT07613840
Recruiting
Not Applicable

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

Arterial Occlusive DiseasesCardiovascular DiseasesCoronary Disease+22 more
Fondazione Ricerca e Innovazione Cardiovascolare ETS576 enrolled1 locationNCT06535568
Recruiting
Not Applicable

The Effects of Dietary Erythritol on Platelet Reactivity and Vascular Inflammation

Platelet Aggregation, SpontaneousVascular Thrombosis
University of California, Davis24 enrolled1 locationNCT05967741
Recruiting
Phase 1

Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II

Diabetes Mellitus, Type 2Type 2 DiabetesAspirin+2 more
Montreal Heart Institute30 enrolled1 locationNCT05702463
Recruiting

Platelet Aggregation in the Diagnosis of Acute Graft Rejection

Kidney Transplant RejectionPlatelet Aggregation
University Hospital, Martin60 enrolled1 locationNCT07275541
Recruiting
Not Applicable

Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions

Coronary Artery DiseasePlatelet Aggregation InhibitorsPercutaneous Coronary Intervention
Insel Gruppe AG, University Hospital Bern2,788 enrolled3 locationsNCT05732701